Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report. (December 2017)

• Record Type: Journal Article
• Authors: Wilcox, Mark H; Dmitrieva, Natalia; Gales, Ana Cristina; Petukhova, Irina; Al-Obeid, Suleiman; Rossi, Flavia; M Blondeau, Joseph
• Is Part Of: Future microbiology. Volume 12:Number 16(2017)
• Page Start: 1525
• Page End: 1534
• Publication Date: 2017-12
• Subjects: antimicrobial susceptibility testing -- surrogate antibiotic -- tedizolid; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2017-0106
• Languages: English
• ISSNs: 1746-0913

Abstract

Inappropriate use and overuse of antibiotics are among the most important factors in resistance development, and effective antibiotic stewardship measures are needed to optimize outcomes. Selection of appropriate antimicrobials relies on accurate and timely antimicrobial susceptibility testing. However, the availability of clinical breakpoints and in vitro susceptibility testing often lags behind regulatory approval by several years for new antimicrobials. A Working Group of clinical/medical microbiologists from Brazil, Canada, Mexico, Saudi Arabia, Russia and the UK recently examined issues surrounding antimicrobial susceptibility testing for novel antibiotics. While commercially available tests are being developed, potential surrogate antibiotics may be used as marker of susceptibility. Using tedizolid as an example of a new antibiotic, this special report makes recommendations to optimize routine susceptibility reporting.